Research

Energy balance

Metformin reduces hepatocyte triglyceride accumulation and plasma triglycerides in NAFLD patients by inhibiting ApoA5 synthesis via the AMPK/LXRα signaling pathway.

For those with fatty liver, metformin may help reduce liver fat by blocking specific proteins (ApoA5) that store fat in the liver. However, it is not currently a recommended or proven standalone treatment for NAFLD in clinical guidelines, so lifestyle changes remain the primary intervention.

ModerateSupportsMEDIUM confidence
Metformin suppresses hepatic accumulation of TG induced by a high-fat diet (HFD) in vivo and in vitro... Metformin reduces hepatic TG accumulation through the inhibition of hepatic ApoA5 synthesis, which is partially mediated through the AMPK/LXRα signaling pathway
Joseph Zhou et al. · International Journal of Molecular Sciences · 2018

Why this rating

Strong mechanistic evidence in cells/mice, but clinical evidence for treating NAFLD is explicitly stated as lacking.

Source

Metformin: An Old Drug with New Applications

Joseph Zhou et al. · International Journal of Molecular Sciences · 2018

DOI 10.3390/ijms19102863

narrative_reviewCited 229×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →